Items tagged with Drug-resistant TB
TB Alliance Stakeholders Association virtual meeting (post)
TB Alliance will convene a special Stakeholders Association meeting as a virtual event on 23 June 2022.
Shorter TB treatment shows promise in Nigeria (post)
-- Nigeria is one of eight countries that accounts for two-thirds of new TB cases
-- A new six-month treatment for TB is being considered for rollout nationwide
-- The WHO-recommended regimen could help combat drug resistance
Study finds TB treatment during pregnancy is safe for mum and baby (post)
Seven out of 10 pregnant women were cured of their multidrug-resistant tuberculosis and delivered healthy babies after taking a medication that had previously been considered unsafe in pregnancy, a new Curtin and Telethon Kids Institute study has found.
South Africa: Shorter, simpler DR-TB regimen expected later this year (post)
Work is underway in South Africa to amend the country’s national guidelines for drug-resistant TB to provide a shorter, six-month, all-oral regimen as a new standard of care treatment.
Being heard on all-oral therapy for resistant TB (post)
A study, published in The Lancet Infectious Diseases, compared outcomes up to 24 months after treatment initiation for patients with rifampicin-resistant TB in South Africa treated with a short, all-oral bedaquiline-containing regimen, or a short, injectable-containing regimen.
25 years of surveillance of drug-resistant tuberculosis: achievements, challenges, and way forward (post)
A personal view, published in The Lancet Infectious Diseases, presented the achievements, challenges, and way forward for the oldest and largest global antimicrobial resistance surveillance system. Hosted by the World Health Organization since 1994, the Global Project on Anti-Tuberculosis Drug Resistance Surveillance has served as a platform for the evaluation of the trends in TB drug resistance for over 25 years at country, regional, and global levels.
Machine learning model helps identify resistance to key antibiotics for treating TB (post)
Tuberculosis (TB) continues to be one of the top ten leading causes of death worldwide with more than 1.3 million reported deaths in 2020.
Drug-resistant TB: Does moxifloxacin prolong QT interval? (post)
Moxifloxacin, when used as part of a shorter treatment regimen for drug-resistant tuberculosis (DR-TB), appears not to increase the risk for prolonging the QT interval (ie, interval between heart contraction and relaxation — the Q through T waves seen on electrocardiogram). This was among study results recently published in the Journal of Clinical Tuberculosis and other Mycobacterial Diseases.
RESIST-TB June 2022 newsletter (post)
RESIST-TB released its June 2022 newsletter with the latest research publications on drug-resistant TB.
Ghana: Study reveals 25.2% of TB patients showed resistance to known TB drugs (post)
Resistance to tuberculosis drugs has become a major threat to the control of the disease globally.
Page 76 of 117 · Total posts: 0
←First 75 76 77 Last→